Z6尊龙
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Prospectus
Announcements
2023.11.23
NOTIFICATION LETTER
2023.11.23
(1) PROPOSED AMENDMENTS TO THE ARTICLES AND RELATED RULES OF PROCEDURES OF THE C...
2023.11.21
PROPOSED AMENDMENTS TO THE ARTICLES AND PROPOSED CHANGE IN USE OF PROCEEDS
2023.10.30
2023 THIRD QUARTERLY REPORT
2023.09.28
Notification of publication of Corporate Communication
2023.09.28
2023 Interim Report
2023.08.30
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
2023.08.21
CHANGE OF FINANCIAL CONTROLLER
2023.07.15
Profit warning
2023.05.23
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
第一页
上一页
2
3
4
5
6
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
【网站地图】
【sitemap】